Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
What is your protocol for intermittent ADT for prostate cancer?
Related Questions
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
In what situations would a standard FDG PET/CT be useful in the evaluation of high risk prostate cancer?
Why are patients getting enzalutamide s/p prostatectomy not candidates for salvage radiation therapy?
Would you consider a treatment break for a patient with metastatic urothelial carcinoma who achieved a near-complete response to Enfortumab?
Would you be more inclined to offer adjuvant therapy to a patient who is age>60 with stage 1B seminoma?
Is there a preferred chemotherapy regimen for chemo-mobilization prior to HDCT for a patient with NSGCT with prior BEP and TIP?
How do you manage critically ill poor risk mixed germ cell tumor patients presenting de novo with extensive lung metastases and severe respiratory failure?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
Is there any evidence for combining surgery and XRT +/- ADT for treatment of localized high risk prostate cancer?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
